Literature DB >> 22939202

Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa.

Petra Schelstraete1, Filomeen Haerynck, Sabine Van daele, Sarah Deseyne, Frans De Baets.   

Abstract

Pseudomonas aeruginosa (Pa) is one of the most common and clinically important pathogens in patients with cystic fibrosis (CF). Chronic Pa colonization in CF patients is associated with increased morbidity and mortality. Pa strains causing early infection are usually antibiotic sensitive and have low bacterial density in the airways. As a result, the treatment strategy has shifted from suppressive therapy in patients chronically colonized by Pa to attempts at early eradication therapy as soon as Pa is detected. In the literature, different treatment regimens have been studied. However, the optimal treatment regimen and duration of treatment are not yet determined. In this article, an overview on the natural history of early Pa colonization and the history of eradication treatment is given. Moreover, the results of the different eradication treatment trials and directions for future research are discussed.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939202     DOI: 10.1016/j.jcf.2012.07.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  19 in total

Review 1.  Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

Authors:  P Vidya; L Smith; T Beaudoin; Y C Yau; S Clark; B Coburn; D S Guttman; D M Hwang; V Waters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01       Impact factor: 3.267

Review 3.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

Review 4.  Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.

Authors:  Ana Margarida Sousa; Maria Olívia Pereira
Journal:  Pathogens       Date:  2014-08-18

5.  The Burkholderia cenocepacia OmpA-like protein BCAL2958: identification, characterization, and detection of anti-BCAL2958 antibodies in serum from B. cepacia complex-infected Cystic Fibrosis patients.

Authors:  Sílvia A Sousa; Mostafa Morad; Joana R Feliciano; Tiago Pita; Soad Nady; Rehab E El-Hennamy; Mona Abdel-Rahman; José Cavaco; Luísa Pereira; Celeste Barreto; Jorge H Leitão
Journal:  AMB Express       Date:  2016-06-21       Impact factor: 3.298

6.  Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance.

Authors:  T Beaudoin; Y C W Yau; P J Stapleton; Y Gong; P W Wang; D S Guttman; V Waters
Journal:  NPJ Biofilms Microbiomes       Date:  2017-10-19       Impact factor: 7.290

7.  Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa.

Authors:  George Tetz; Daria Vikina; Victor Tetz
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-03-22       Impact factor: 3.944

8.  Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.

Authors:  Emma Reece; Ricardo Segurado; Abaigeal Jackson; Siobhán McClean; Julie Renwick; Peter Greally
Journal:  BMC Pulm Med       Date:  2017-04-21       Impact factor: 3.317

Review 9.  The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-10-27       Impact factor: 2.849

10.  Quantitative assessment of individual populations within polymicrobial biofilms.

Authors:  Susana Patrícia Lopes; Nuno Filipe Azevedo; Maria Olívia Pereira
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.